Frequency of Acne and Acne Scars in Patients with Neurofibromatosis 1
DOI:
https://doi.org/10.2340/actadv.v104.18621Keywords:
Neurofibromatosis 1, Recklinghausen’s disease, inflammation, acne, scar, acne scarAbstract
Abstract is missing (Short communication)
Downloads
References
Riccardi VM. Neurofibromatosis. Neurol Clin 1987; 5: 337-349.
https://doi.org/10.1016/S0733-8619(18)30909-5 DOI: https://doi.org/10.1016/S0733-8619(18)30909-5
Niimura M. Neurofibromatosis in Japan. In: Ishibashi Y, Hori Y, editors. Tuberous sclerosis and neurofibromatosis: epidemiology, pathophysiology, biology and management. Amsterdam: Excerpta Medica; 1990: p. 22-31.
Koga M, Koga K, Nakayama J, Imafuku S. Anthropometric characteristics and comorbidities in Japanese patients with neurofibromatosis type 1: a single institutional case-control study. J Dermatol 2014; 41: 885-889.
https://doi.org/10.1111/1346-8138.12611 DOI: https://doi.org/10.1111/1346-8138.12611
Yoshida Y, Ehara Y, Koga M, Imafuku S, Yamamoto O. Epidemiological analysis of major complications requiring medical intervention in patients with neurofibromatosis 1. Acta Derm Venereol 2018; 98: 753-756.
https://doi.org/10.2340/00015555-2975 DOI: https://doi.org/10.2340/00015555-2975
Miyawaki T, Billings B, Har-Shai Y, Agbenorku P, Kokuba E, Moreira-Gonzalez A, et al. Multicenter study of wound healing in neurofibromatosis and neurofibroma. J Craniofac Surg 2007; 18: 1008-1011.
https://doi.org/10.1097/scs.0b013e31811f3587 DOI: https://doi.org/10.1097/scs.0b013e31811f3587
Hayashi N, Akamatsu H, Kawashima M, Acne Study Group. Establishment of grading criteria for acne severity. J Dermatol 2008; 35: 255-260.
https://doi.org/10.1111/j.1346-8138.2007.00403.x-i1 DOI: https://doi.org/10.1111/j.1346-8138.2007.00403.x-i1
National Institutes of Health Consensus Development Conference. Neurofibromatosis: Conference statement. Arch Neurol 1988; 45: 575-578.
https://doi.org/10.1001/archneur.1988.00520290115023 DOI: https://doi.org/10.1001/archneur.1988.00520290115023
Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48: 452-458.
https://doi.org/10.1038/bmt.2012.244 DOI: https://doi.org/10.1038/bmt.2012.244
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016; 375: 2550-2560.
https://doi.org/10.1056/NEJMoa1605943 DOI: https://doi.org/10.1056/NEJMoa1605943
Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist 2020; 25: e1109-e1116.
https://doi.org/10.1634/theoncologist.2020-0069 DOI: https://doi.org/10.1634/theoncologist.2020-0069
Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol 2014; 55: 250-254.
https://doi.org/10.1111/ajd.12124 DOI: https://doi.org/10.1111/ajd.12124
Wataya-Kaneda M, Nagai H, Ohno Y, Yokozeki H, Fujita Y, Niizeki H, et al. Safety and efficacy of the sirolimus gel for TSC patients with facial skin lesions in a long-term, open-label, extension, uncontrolled clinical trial. Dermatol Ther (Heidelb) 2020; 10: 635-650.
https://doi.org/10.1007/s13555-020-00387-7 DOI: https://doi.org/10.1007/s13555-020-00387-7
Published
How to Cite
License
Copyright (c) 2024 Monji Koga, Shinichi Imafuku
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
